MoonLake Immunotherapeutics (MLTX)
43.62
+0.80
(+1.86%)
USD |
NASDAQ |
May 02, 11:39
MoonLake Immunotherapeutics Net Income (TTM): -36.01M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -36.01M |
| September 30, 2023 | -45.68M |
| June 30, 2023 | -46.36M |
| March 31, 2023 | -48.34M |
| Date | Value |
|---|---|
| December 31, 2022 | -55.22M |
| September 30, 2022 | -44.40M |
| June 30, 2022 | -66.97M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-66.97M
Minimum
Jun 2022
-36.01M
Maximum
Dec 2023
-49.00M
Average
-46.36M
Median
Jun 2023
Net Income (TTM) Benchmarks
| Qiagen NV | -- |
| LENZ Therapeutics Inc | -- |
| AC Immune SA | -60.14M |
| CRISPR Therapeutics AG | -153.61M |
| Addex Therapeutics Ltd | -11.76M |